Dublin, May 07, 2024 (GLOBE NEWSWIRE) -- The "Cancer Monoclonal Antibody Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.
Cancer Monoclonal Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cancer monoclonal antibody deals entered into by the world's leading biopharma companies. Fully revised and updated, the report provides details of cancer monoclonal antibody deals from 2016 to 2024.
The report provides a detailed understanding and analysis of how and why companies enter cancer monoclonal antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 599 cancer monoclonal antibody deals announced since 2016 including financial terms where available including links to online deal records of actual cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The report also includes numerous table and figures that illustrate the trends and activities in cancer monoclonal antibody deal making since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key Benefits
- Understand deal trends since 2016
- Browse cancer monoclonal antibody collaboration and licensing deals
- Benchmark analysis - identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, deal type and therapy area
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in cancer monoclonal antibody dealmaking
2.1. Introduction
2.2. Cancer monoclonal antibody deals over the years
2.3. Most active cancer monoclonal antibody dealmakers
2.4. Cancer monoclonal antibody deals by deal type
2.5. Cancer monoclonal antibody deals by therapy area
2.6. Cancer monoclonal antibody deals by industry sector
2.7. Deal terms for cancer monoclonal antibody deals
2.7.1 Cancer monoclonal antibody deals headline values
2.7.2 Cancer monoclonal antibody deal upfront payments
2.7.3 Cancer monoclonal antibody deal milestone payments
2.7.4 Cancer monoclonal antibody royalty rates
Chapter 3 - Leading cancer monoclonal antibody deals
3.1. Introduction
3.2. Top cancer monoclonal antibody deals by value
Chapter 4 - Most active cancer monoclonal antibody dealmakers
4.1. Introduction
4.2. Most active cancer monoclonal antibody dealmakers
4.3. Most active cancer monoclonal antibody deals company profiles
Chapter 5 - Cancer monoclonal antibody contracts dealmaking directory
5.1. Introduction
5.2. Cancer monoclonal antibody contracts dealmaking directory
Chapter 6 - Cancer monoclonal antibody dealmaking by technology type
Deal directory
- Deal directory - Cancer monoclonal antibody deals by company A-Z
- Deal directory - Cancer monoclonal antibody deals by deal type
- Deal directory - Cancer monoclonal antibody deals by therapy area
- Deal type definitions
Companies Featured
- 1ST Biotherapeutics
- 3D Medicines
- 3SBio
- 4D Pharma
- A*STAR Agency for Science
- Technology and Research
- Abbvie
- AbClon
- Abdul Latif Jameel Health
- Abmuno Therapeutics
- Abpro
- Abveris
- Abzena
- Accord Healthcare
- Acerta Pharma
- Adagene
- Adaptimmune
- Adaptive Biotechnologies
- Adimab
- Adlai Nortye
- Aduro BioTech
- Advaxis
- Aeglea BioTherapeutics
- AffaMed Therapeutics
- Affimed Therapeutics
- Agenus Bio
- Agilent Technologies
- AIM ImmunoTech
- Ajinomoto
- Akeso Biopharma
- Alligator Bioscience
- Alloy Therapeutics
- Almac Group
- Alphamab Biopharmaceuticals
- Alpine Immune Sciences
- Alvogen
- Alvotech
- ALX Oncology
- Ambrx
- Amgen
- Amneal Pharmaceuticals
- Ankyra Therapeutics
- Antengene
- Antigen Express
- Aperion Biologics
- Apexigen
- Aptevo Therapeutics
- Arch Oncology
- Arcus Biosciences
- argenx
- Arovella Therapeutics
- Array Biopharma
- Ascentage Pharma
- Asher Biotherapeutics
- Asieris MediTech
- Aslan Pharma
- Astellas Pharma
- Astex Pharmaceuticals
- AstraZeneca
- Atara Biotherapeutics
- Athenex
- Atlab Pharma
- Atlante Biotech
- Atlas Antibodies
- AVEO Oncology
- Basilea Pharmaceutica
- Bavarian Nordic
- Baxalta
- Bayer
- BeiGene
- Beijing InnoCare Pharma
- BerGenBio
- Betta Pharmaceuticals
- Bio-Manguinhos/Fiocruz
- Bio-Thera Solutions
- BioAtla
- BioCity Biopharma
- Biocon
- Biodesix
- BioInvent
- BiolineRX
- BioMarker Strategies
- Biomm
- Biomunex Pharmaceuticals
- Bioncotech Therapeutics
- Biond Biologics
- BioNTech
- Biosion
- Biothera Pharmaceuticals
- Biotheus
- BioXcel
- BJ Bioscience
- Blackstone
- Boehringer Ingelheim
- Bolt Biotherapeutics
- Boston Immune Technologies and Therapeutics
- Bpifrance
- BridgeBio Pharma
- Bright Peak Therapeutics
- Bristol-Myers Squibb
- C-Bridge Capital
- California Institute for Regenerative Medicine
- Calithera Biosciences
- CanariaBio
- Cancer Focus Fund
- Cancer Prevention and Research Institute of Texas
- Cancer Research UK
- Cancer Science Institute of Singapore
- CanCure
- Candel Therapeutics
- Cantargia
- Caris Life Sciences
- CARsgen
- Cartexell
- CBT Pharmaceuticals
- Celgene
- Cellectis
- Celltrion
- Celularity
- Cend Therapeutics
- Centre for Drug Research and Development (CDRD)
- CG Oncology
- Champions Oncology
- Checkmate Pharmaceuticals
- Chi-Med
- Chime Biologics
- Chiome Bioscience
- Cilag AG
- Cipla
- Circio
- City of Hope Comprehensive Cancer Center
- Clinica Universidad Navarra
- Clovis Oncology
- CMAB Biopharma
- Coherus Biosciences
- Cold Genesys
- Columbia University
- Compass Therapeutics
- Compugen
- Convergent Therapeutics
- Corvus Pharmaceuticals
- Covalab
- Creative Biolabs
- Crescendo Biologics
- Crown Bioscience
- CStone Pharmaceuticals
- Cue Biopharma
- Cullinan Oncology
- Curative Biotechnology
- Curis
- Cytodyn
- Cytovation
- Daiichi Sankyo
- Debiopharm
- Department of Defense
- Diaprost
- Distributed Bio
- Dr. Reddy's Laboratories
- eFFECTOR Therapeutics
- EirGenix
- Eisai
- Elevar Therapeutics
- Elevation Oncology
- Elicio Therapeutics
- Eli Lilly
- ElsaLys Biotech
- Enlivex
- Enzolytics
- EpiThany
- EQRx
- Erasca
- Erasmus University Medical Center
- Essex Bio-Technology
- Eucure Biopharma
- Eurofarma
- European Union Regional Development Fund
- EUSA Pharma
- Eutilex
- Evaxion Biotech
- Everest Medicines
- Evopoint Biosciences
- Excellmab
- Exelixis
- F-Star Therapeutics
- FatiAbGen
- Five Prime Therapeutics
- FLX Bio
- Formosa Pharmaceuticals
- Forty Seven
- Fosun Kite Biotechnology
- Fosun Pharmaceutical
- Fred Hutchinson Cancer Research Center
- Fuhong Hanlin
- Fusion Pharmaceuticals
- Galaxy Biotech
- Galecto
- GBI BioManufacturing
- Genentech
- Genexine
- GenFleet Therapeutics
- Genmab
- Genome and Company
- Genor Biopharma
- Genprex
- GenScript Biotech
- Georgetown University
- Gilead Sciences
- Glenmark Pharmaceuticals
- Glycotope Biotechnology
- Glythera
- Gossamer Bio
- GO Therapeutics
- Gradalis
- Gritstone Bio
- GSK
- H-Immune
- H3 Biomedicine
- Halozyme Therapeutics
- Harbour Biomed
- Heidelberg Pharma
- Henlius Biotech
- HiberCell
- HIBio
- HiFiBio
- Highlight Therapeutics
- Hikma Pharmaceuticals
- Hisun BioRay
- Hoffmann La Roche
- Hookipa Pharma
- Hualan Genetic
- Humanigen
- Hummingbird Bioscience
- Hutchison MediPharma
- Huyabio International
- Hypospray Pharma
- I-mab
- iBio
- IcanoMAB
- iDD Biotech
- IDEAYA Biosciences
- ImCheck Therapeutics
- ImClone Systems
- Immatics Biotechnologies
- Immix Biopharma
- Immune-Onc Therapeutics
- ImmuneOncia Therapeutics
- Immune Pharmaceuticals
- Immunicum
- Immunitas Therapeutics
- ImmunoChina Pharmaceuticals
- Immunocore
- ImmunoGen
- Immunomedics
- Immunovaccine
- Immutep
- IMPACT Therapeutics
- Imugene
- IMV
- Incyte
- Infinity Pharmaceuticals
- InflaRx
- Innate Pharma
- Innovent Biologics
- Inovio
- Inspirna
- Institut Bergonie
- Intas Pharmaceuticals
- Integral Molecular
- Intensity Therapeutics
- InxMed
- IO Biotech
- Ionova
- IONTAS
- Ipsen
- IRBM
- ISA Pharmaceuticals
- Italian Association for the Study of Pancreas
- iTeos Therapeutics
- Jacobio Pharmaceuticals
- Janssen Biotech
- Janssen Research & Development
- Jazz Pharmaceuticals
- JHL Biotech
- Jiangsu Alphamab
- Jiangsu Hansoh Pharmaceutical
- Jiangsu Hengrui Medicine
- Jiangsu Hengrui Pharmaceuticals
- Johns Hopkins University
- Jounce Therapeutics
- Junshi Biosciences
- KAHR Medical
- Kalbe Genexine Biologics
- Kelun-Biotech Biopharmaceutical
- Kineta
- Kiniksa Pharmaceuticals
- Kintor
- Kite Pharma
- Kolltan Pharmaceuticals
- Kymab
- Laekna
- Lassen Therapeutics
- Lava Therapeutics
- Leap Therapeutics
- Leica Biosystems
- LEO Pharma
- Les Laboratoires Servier
- Leukemia & Lymphoma Society
- LG Life Sciences
- LifeMax Laboratories
- Linnaeus Therapeutics
- Livzon Mabpharm
- Lonza
- Lumos Pharma
- Lunit
- Lupagen
- Lyvgen Biopharma
- MAB Discovery
- mAbsolve
- mAbXience
- Macrogenics
- MAIA Biotechnology
- Manhattan BioSolutions
- Massachusetts General Hospital
- Mayo Clinic
- MD Anderson Cancer Center
- Medical Research Council
- Medicenna Therapeutics
- MedImmune
- Medison Pharma
- Memorial Sloan Kettering Cancer Center
- Merck and Co
- Merck KGaA
- Merck Sharpe & Dohme
- Mereo BioPharma
- Merrimack Pharmaceuticals
- Merus
- Microbiotica
- Mitra Biotech
- Molcure
- Moleculin Biotech
- Monopar Therapeutics
- MorphoSys
- Morphotek
- Mount Sinai Health System
- MSD
- MS Pharma
- Mundipharma
- Mustang Bio
- Mylan Pharmaceuticals
- Myriad Genetics
- Nanjing Leads Biolabs
- Nascent Biotech
- National Cancer Institute
- National Center for Tumor Diseases
- National Comprehensive Cancer Network (NCCN)
- National Institutes of Health
- National University Cancer Institute
- Navrogen
- Nectin Therapeutics
- Nektar Therapeutics
- Nelum Pharma
- NeoImmuneTech
- Neoleukin Therapeutics
- Neon Therapeutics
- NETRIS Pharma
- Neuroblastoma and Medulloblastoma Translational Research
- Nexvet
- NGM Biopharmaceuticals
- NiKang Therapeutics
- NKGen Biotech
- NKMax America
- Nordic Society of Gynaecological Oncology
- Nouscom
- NovalGen
- Novartis
- Novelogics Biotechnology
- Novocure
- Noxopharm
- Noxxon Pharma
- Numab
- Nykode Therapeutics
- OBI Pharma
- Olatec Therapeutics
- Olivia Newton-John Cancer Research Institute
- OncoC4
- OncoCare Therapeutics
- OncoImmune
- Oncologie
- Oncolytics Biotech
- OncoQuest
- OncoResponse
- OncoSec Medical
- OncoVerity
- Oncternal Therapeutics
- Oncurious
- OncXerna Therapeutics
- Ono Pharmaceutical
- Ordaos Bio
- OSE Immunotherapeutics
- Oxford BioTherapeutics
- Panacea Pharmaceuticals
- Pascal Biosciences
- PDS Biotechnology
- Peregrine Pharmaceuticals
- Personal Genome Diagnostics
- Personalis
- Pfizer
- Phanes Therapeutics
- PharmAbcine
- Pharmapark
- Pieris Pharmaceuticals
- Pierre Fabre
- Pionyr Immunotherapeutics
- PlantForm
- PlantPraxis Biotecnologia
- PMV Pharma
- Pneuma Respiratory
- POINT Biopharma
- Portage Biotech
- Poseida Therapeutics
- Precision BioSciences
- Prestige BioPharma
- ProBioGen
- Progenetics
- Progenics Pharmaceuticals
- Promega
- ProtoKinetix
- PT Etana Biotechnologies
- PULSALYS
- PureTech Health
- Pyxis Oncology
- QBiotics
- Qiagen
- Quantum Leap Health Care Collaborative
- Quest PharmaTech
- Qurient
- Radboud University Nijmegen Medical Centre
- RefleXion Medical
- Regeneron Pharmaceuticals
- Regnum
- RemeGen
- Replimune
- Rexahn Pharmaceuticals
- Roche
- Roswell Park Cancer Institute
- RubrYc Therapeutics
- Rxilient Biotech
- Rznomics
- Saccharo
- Samsung Bioepis
- Samsung Biologics
- Samyang Biopharmaceuticals
- Sandoz
- Sanofi
- Sanofi-Aventis
- Sarah Cannon Research Institute
- SATT Sud-Est
- Scandion Oncology
- Schrodinger
- SciClone Pharmaceuticals
- Scripps Research Institute
- Seagen
- Seattle Genetics
- Seismic Bio
- Selecxine
- Selexis
- SELLAS Life Sciences Group
- Sensei Biotherapeutics
- Seven and Eight Biopharmaceuticals
- SevenScore Pharmaceuticals
- Sharp HealthCare
- Shenogen Pharma
- Shenzhen Chipscreen Biosciences
- Simcere Pharmaceuticals
- Simcha Therapeutics
- Sirnaomics
- Sonnet BioTherapeutics
- Sorrento Therapeutics
- Sosei Heptares
- SOTIO
- Spanish National Research Council
- Specialised Therapeutics
- Specialized Medical Services-oncology
- Strata Oncology
- Sud Investments
- Surface Oncology
- Syndax Pharmaceuticals
- Synlogic
- Syros Pharmaceuticals
- T-Cure Bioscience
- Taiho
- Takeda Pharmaceutical
- Talem Therapeutics
- TARIS Biomedical
- Tavotek Biotherapeutics
- TCR2 Therapeutics
- Telix Pharmaceuticals
- Tempest Therapeutics
- TeneoBio
- Teon Therapeutics
- Tesaro
- Tessa Therapeutics
- Tetragenetics
- Teva Pharmaceutical Industries
- TG Therapeutics
- Theranyx
- Thermo Fisher Scientific
- ThromboGenics
- TILT Biotherapeutics
- Tiziana Life Sciences
- Tizona Therapeutics
- Tmunity Therapeutics
- Torque Therapeutics
- TRACON Pharmaceuticals
- Transcenta
- Transgene
- TransThera
- Trianni
- Trieza Therapeutics
- Trio Pharmaceuticals
- Triumvira Immunologics
- Turgut Ilaclari
- Twist Bioscience
- UbiVac
- UCB
- Universite Claude Bernard Lyon
- University of Bergen
- University of British Columbia
- University of California
- San Diego
- University of California Los Angeles
- University of California San Francisco
- University of Florida
- University of New Mexico
- University of Wisconsin Carbone Cancer Center (UWCCC)
- UroGen Pharma
- Vaccinex
- Vaximm
- Vcell Healthcare
- Vedanta Biosciences
- Verseau Therapeutics
- Viela Bio
- Vyriad
- Wellmarker Bio
- Werewolf Therapeutics
- Wilex
- WindMIL Therapeutics
- WuXi Biologics
- Wuxi Shuangliang Biotechnology
- Xencor
- Xilio Therapeutics
- Xoma
- Xuanzhu Biopharma
- Xyphos Biosciences
- Y-Biologics
- Y-mAbs Therapeutics
- Yale Cancer Center
- Yale University
- ZAI Laboratory
- Zenoaq
- Zhejiang Bossan Pharmaceutical
- Zhejiang Hisun Pharmaceutical
- Zhejiang Huahai Pharmaceutical
- Zydus Cadila
For more information about this report visit https://www.researchandmarkets.com/r/c7c1te
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.